Journal: Synthetic and Systems Biotechnology

Article Title: Metabolic reprogramming of abscisic acid-producing strain Botrytis cinerea TB-31 toward terpenoid biosynthesis using a CRISPR/Cas9 ribonucleoprotein system

doi: 10.1016/j.synbio.2025.12.002

Figure Lengend Snippet: Transcriptomic analysis of B. cinerea strains TB-31, △ bcaba3 , and △ bcaba1234 . (A)∼(B) Regression analysis between transcriptomic data (RNA-seq) and RT‒qPCR validation. △ bcaba3 vs. TB-31: R 2 = 0.94, P < 0.001 (A); △ bcaba1234 vs. TB-31: R 2 = 0.97, P < 0.001 (B). (C) Heatmap of the relative transcriptional levels of the genes in the MVA pathway in △ bcaba1234 compared with those in TB-31. Gene transcription levels were normalized using Z score transformation, calculated as (X-mean)/SD, to represent the number of standard deviations above or below the mean transcription level. Upregulated genes are highlighted in red, while downregulated genes are shown in blue. The data are derived from three independent biological replicates. (D) Heatmap of the relative transcriptional levels of DEGs involved in other secondary metabolism pathways in △ bcaba1234 compared with those in TB-31. (E) Heatmap of the relative transcriptional levels of genes involved in intracellular primary metabolic pathways in the △ bcaba1234 strain compared with those in the TB-31 strain. Metabolic pathways are marked with gray boxes. PPP: pentose phosphate pathway; TCA: tricarboxylic acid cycle; GYC: glyoxylate cycle.

Article Snippet: The sgRNAs were transcribed using the T7 High Yield RNA Transcription Kit (Nanjing Vazyme Biotech Co., Ltd., Nanjing, China), and then purified using the RNA Clean & Concentrator Kit (Zymo Research Corp., Irvine, California, USA).

Techniques: RNA Sequencing, Biomarker Discovery, Transformation Assay, Derivative Assay

Journal: Molecular Therapy Oncology

Article Title: Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption

doi: 10.1016/j.omton.2026.201133

Figure Lengend Snippet: The antitumor effects of mPsiP@miLAND on PC-3 subcutaneous tumor model (A) Brief description of the experimental process and grouping information. (B) Tumor growth curves and (C) bodyweight changes of the treated animals during the entire study period. (D) Tumor weights, (E) serum biochemical indicators, and (F) relative mRNA expression of PARP1, recorded or analyzed at the end of the study. Seven indicators including creatine kinase (CK, U/liter), aspartate aminotransferase (AST, U/liter), alkaline phosphatase (ALP, U/liter), total protein (TP, g/liter), urea nitrogen (UREA, mmol/L), serum creatinine (CREA, mmol/L), and triglyceride (TG, mmol/L) were recorded. (G) Analysis of PI3K-Akt signaling, glycolysis, apoptosis, transcription, and translation in tumors after treatment. (H) The impacts of the formulations on tumor proliferation and apoptosis, as measured by Ki67 (top) and TUNEL (bottom) staining. ∗ p < 0.05, considered as statistically significant; ∗∗∗∗ p < 0.0001, each bar chart represents the mean ± SD.

Article Snippet: BstZ17I-HF endonuclease (R3594L), rCutSmart Buffer (B6004S), and HiScribe T7 ARCA mRNA in vitro transcription kit (E2060S) were purchased from NEB (MA, USA).

Techniques: Expressing, TUNEL Assay, Staining